[Development of therapeutic agents related to urotensin II].
Mori
Masaaki
M
Discovery Research Laboratories, Takeda Chemical Industries, Ltd.
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D002839:Chromans / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D006801:Humans; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000737:chemistry / Q000494:pharmacology; D014579:Urotensins / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000494:pharmacology / Q000502:physiology; D014661:Vasoconstriction
C468786:3-(4-chlorophenyl)-3-(2-(dimethylamino)ethyl)isochroman-1-one; C092829:BIM 23127; D002839:Chromans; C121568:PRL 2903; C119471:PRL 2915; D010446:Peptide Fragments; D010456:Peptides, Cyclic; C473646:SB-710411; D014579:Urotensins; C466635:aspartyl-cyclo(penicillamyl-phenylalanyl-tryptophyl-lysyl-tyrosyl-cysteinyl)valine; C492079:urotensin II (4-11), Pen(5)-Trp(7)-Orn(8)-; C029677:urotensin II